<HashMap><database>biostudies-other</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Prof. Wenqi Wang</submitter><funding>HHS | National Institutes of Health (NIH)</funding><funding>U.S. Department of Defense (DOD)</funding><funding>American Cancer Society (ACS)</funding><funding>HHS | NIH | National Cancer Institute (NCI)</funding><funding>HHS | NIH | National Institute of General Medical Sciences (NIGMS)</funding><journal>The EMBO Journal</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-SCDT-EMBOJ-2019-102406</full_dataset_link><abstract>The Hippo pathway, which plays a critical role in organ size control and cancer, features numerous WW domain-based protein-protein interactions. However, ~100 WW domains and 2,000 PY motif-containing peptide ligands are found in the human proteome, raising a "WW-PY" binding specificity issue in the Hippo pathway. In this study, we have established the WW domain binding specificity for Hippo pathway components and uncovered a unique amino acid sequence required for it. By using this criterion, we have identified a WW domain-containing protein, STXBP4, as a negative regulator of YAP. Mechanistically, STXBP4 assembles a protein complex comprising ?-catenin and a group of Hippo PY motif-containing components/regulators to inhibit YAP, a process that is regulated by actin cytoskeleton tension. </abstract><repository>biostudies-other</repository><funding_grant_id>W81XWH-09-1-0409</funding_grant_id><funding_grant_id>GM055246</funding_grant_id><funding_grant_id>P30 CA062203</funding_grant_id><funding_grant_id>RSG-18-009-01-CCG</funding_grant_id><funding_grant_id>GM130367</funding_grant_id><funding_grant_id>GM126048</funding_grant_id><funding_grant_id>T32 EB009418-08</funding_grant_id><pubmed_authors>Vy, Thuy Duong</pubmed_authors><pubmed_authors>Prof. Junjie Chen</pubmed_authors><pubmed_authors>Kimberly Chuc</pubmed_authors><pubmed_authors>Sunwoo Oh</pubmed_authors><pubmed_authors>Albert, Paul Ta</pubmed_authors><pubmed_authors>Olga Razorenova</pubmed_authors><pubmed_authors>Yuxuan Chen</pubmed_authors><pubmed_authors>Prof. Ray Luo</pubmed_authors><pubmed_authors>Prof. Wenqi Wang</pubmed_authors><pubmed_authors>Xu Li</pubmed_authors><pubmed_authors>Han Han</pubmed_authors><pubmed_authors>Shiji Zhao</pubmed_authors><pubmed_authors>Ms. Bing Yang</pubmed_authors><pubmed_authors>Amal, El Ali</pubmed_authors><pubmed_authors>Rebecca Vargas</pubmed_authors><pubmed_authors>Gayoung Seo</pubmed_authors></additional><is_claimable>false</is_claimable><name>Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor</name><description>The Hippo pathway, which plays a critical role in organ size control and cancer, features numerous WW domain-based protein-protein interactions. However, ~100 WW domains and 2,000 PY motif-containing peptide ligands are found in the human proteome, raising a "WW-PY" binding specificity issue in the Hippo pathway. In this study, we have established the WW domain binding specificity for Hippo pathway components and uncovered a unique amino acid sequence required for it. By using this criterion, we have identified a WW domain-containing protein, STXBP4, as a negative regulator of YAP. Mechanistically, STXBP4 assembles a protein complex comprising ?-catenin and a group of Hippo PY motif-containing components/regulators to inhibit YAP, a process that is regulated by actin cytoskeleton tension. </description><dates><release>2020-01-13T21:00:54Z</release><modification>2020-01-13T21:00:54Z</modification><creation>2020-01-13T21:00:54Z</creation></dates><accession>S-SCDT-EMBOJ-2019-102406</accession><cross_references><doi>10.15252/embj.2019102406</doi></cross_references></HashMap>